DXCM — DexCom, Inc.
$83.33
+$1.94 (+2.38%)
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
Market Cap
$31.08B
Forward P/E
26.6x
52-Week Range
DXCM Price History
Current price
$83.33
DXCM return (1Y)
+39.5%
S&P 500 return (1Y)
+12.2%
vs S&P 500
+27.3 pts
Revenue vs. Net Income
$4.7B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$1.1B
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
26.4%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.8x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
7.8%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
-1.7%
Net buyback · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
